Alvotech
NASDAQ: ALVO · HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC
Updated 2026-06-05
Alvotech (ALVO) Financial statements
SEC filings — annual and quarterly data.
Margin trends — annual
| Year | Revenue | Net income | Gross margin | Op. margin | Profit margin |
|---|---|---|---|---|---|
| 2019 | $31.92M | $-209.88M | 100.00% | -192.52% | -657.55% |
| 2020 | $66.62M | $-170.04M | 100.00% | -206.46% | -255.26% |
| 2021 | $36.77M | $-101.50M | 100.00% | -640.31% | -276.04% |
| 2022 | $83.03M | $-513.58M | 22.80% | -417.25% | -618.55% |
| 2023 | $91.43M | $-551.73M | -75.93% | -388.11% | -603.42% |
| 2024 | $489.68M | $-231.86M | 62.16% | 14.22% | -47.35% |
| 2025 | $586.32M | $27.92M | 59.82% | 13.34% | 4.76% |
Frequently asked questions
What is Alvotech's revenue?
Alvotech's trailing twelve-month revenue is $562.04M. Revenue is the top line the whole model builds on, and at this scale the question shifts from how fast it grows to whether margins hold as it compounds.
How profitable is ALVO?
In its most recent fiscal year, ALVO ran a gross margin of 59.82%, an operating margin of 13.34%, and a net margin of 4.76%. Margins this high mean most of each extra dollar of revenue drops through to profit, which is the signature of real pricing power.
How much free cash flow does ALVO generate?
ALVO produced $-114.67M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.
Is ALVO's balance sheet healthy?
ALVO holds $172.36M in cash and equivalents against $1.26B in long-term debt, on $-284.49M of shareholder equity. That debt is best read against the cash flow the business throws off each year.